Dr Emma Tallantyre

2021

• Garjani, A.et al. 2021. COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. Multiple Sclerosis and Related Disorders 52, article number: 102939. (10.1016/j.msard.2021.102939)
• Lipp, I.et al. 2021. Predictors of training-related improvement in visuomotor performance in patients with multiple sclerosis: a behavioural and MRI study. Multiple Sclerosis 7(7), pp. 1088-1101. (10.1177/1352458520943788)
• Latchem-Hastings, J.et al. 2021. Lifestyle, exercise and activity package for people living with progressive multiple sclerosis (LEAP-MS): protocol for a single-arm feasibility study. Pilot and Feasibility Studies 7, article number: 111. (10.1186/s40814-021-00852-w)
• Tallantyre, E.et al. 2021. Neurological updates: neurological complications of CAR-T therapy. Journal of Neurology 268, pp. 1544-1554. (10.1007/s00415-020-10237-3)
• Winter, M.et al. 2021. Tract-specific MRI measures explain learning and recall differences in multiple sclerosis. Brain Communications 3(2), article number: fcab065. (10.1093/braincomms/fcab065)
• Busse, M.et al. 2021. A web-based physical activity intervention for people with progressive Multiple Sclerosis: application of consensus-based intervention development guidance. BMJ Open 11(3), article number: e045378. (10.1136/bmjopen-2020-045378)
• Evangelou, N.et al. 2021. Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register. Journal of Neurology, Neurosurgery and Psychiatry 92, pp. 107-109. (10.1136/jnnp-2020-324449)
• Hares, K.et al. 2021. KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis. Journal of Neurology (10.1007/s00415-020-10373-w)

2020

• Zelek, W. M.et al. 2020. Cerebrospinal fluid complement system biomarkers in demyelinating disease. Multiple Sclerosis 26(14), pp. 1929-1937. (10.1177/1352458519887905)
• Anderson, V.et al. 2020. Serum neurofilament-light concentration and real-world outcome in MS. Journal of the Neurological Sciences 417, article number: 117079. (10.1016/j.jns.2020.117079)
• Ontaneda, D.et al. 2020. Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. Contemporary Clinical Trials 95 (10.1016/j.cct.2020.106009)
• Saxena, G.et al. 2020. Detecting and predicting neutralization of alemtuzumab responses in multiple sclerosis. Neurology, Neuroimmunology and Neuroinflammation 7(4), article number: e767. (10.1212/NXI.0000000000000767)
• Tallantyre, E.et al. 2020. Eligibility and implementation of disease-modifying therapy for primary progressive multiple sclerosis in a UK cohort. Multiple Sclerosis and Related Disorders 42, article number: 102056. (10.1016/j.msard.2020.102056)
• Tallantyre, E.et al. 2020. Achieving effective patient and public involvement in international clinical trials in neurology. Neurology 10(3), pp. 265-272. (10.1212/CPJ.0000000000000739)
• Saxena, G.et al. 2020. Detecting and predicting neutralization of alemtuzumab responses in MS. Neurology, Neuroimmunology and Neuroinflammation 7(4), article number: e767. (10.1212/NXI.0000000000000767)
• Lipp, I.et al. 2020. Tractography in the presence of multiple sclerosis lesions. NeuroImage 209, article number: 116471. (10.1016/j.neuroimage.2019.116471)
• Allen, C. M.et al. 2020. Clinical observation during alemtuzumab administration. Multiple Sclerosis and Related Disorders 37, article number: 101412. (10.1016/j.msard.2019.101412)
• Chamberland, M.et al. 2020. Beyond lesion-load: tractometry-based metrics for characterizing white matter lesions within fibre pathways. Presented at: MICCAI 2020 International Workshop on Computational Diffusion MRI (CDMRI 2020), Virtual, 8 October 2020.

2019

• Davda, N., Tallantyre, E. and Robertson, N. P. 2019. Early MRI predictors of prognosis in multiple sclerosis. Journal of Neurology 266(12), pp. 3171-3173. (10.1007/s00415-019-09589-2)
• Ontaneda, D.et al. 2019. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurology 18(10), pp. 973-980. (10.1016/S1474-4422(19)30151-6)
• Abdullah, A. A. N. and Tallantyre, E. 2019. HSV-2 radiculitis: An unusual presentation mere days after genital infection. Clinical Neurology and Neurosurgery 185, article number: 105429. (10.1016/j.clineuro.2019.105429)
• Castle, D.et al. 2019. Using biomarkers to predict clinical outcomes in multiple sclerosis. Practical Neurology 19(4), pp. 342-349. (10.1136/practneurol-2018-002000)
• Lipp, I.et al. 2019. Comparing MRI metrics to quantify white matter microstructural damage in multiple sclerosis. Human Brain Mapping 40(10), pp. 2917-2932. (10.1002/hbm.24568)
• Harding, K.et al. 2019. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurology 76(5), pp. 536-541. (10.1001/jamaneurol.2018.4905)
• Whittam, D. H.et al. 2019. Rituximab in neurological disease: principles, evidence and practice. Practical Neurology 19(1), pp. 5-10. (10.1136/practneurol-2018-001899)

2018

• Tallantyre, E. C., Robertson, N. P. and Jolles, S. 2018. Secondary antibody deficiency in neurology. Current Opinion in Allergy and Clinical Immunology 18(6), pp. 481-488. (10.1097/ACI.0000000000000485)
• Robertson, J. and Tallantyre, E. 2018. Nerve sheath tumours. Journal of Neurology 265(12), pp. 3034-3035. (10.1007/s00415-018-9098-y)
• Beesley, R.et al. 2018. Impact of the 2017 revisions to McDonald criteria on the diagnosis of Multiple Sclerosis. Multiple Sclerosis 24(13), pp. 1786-1787. (10.1177/1352458518778007)
• Harding, K.et al. 2018. A contemporary study of mortality in the multiple sclerosis population of south east Wales. Multiple Sclerosis and Related Disorders 25, pp. 186-191. (10.1016/j.msard.2018.08.001)
• Tallantyre, E. C.et al. 2018. How common is truly benign MS in a UK population?. Journal of Neurology, Neurosurgery and Psychiatry 90, pp. 522-528. (10.1136/jnnp-2018-318802)
• Alsaeed, M.et al. 2018. Multiple sclerosis: long-term outcomes in ethnic minorities. analysis of a UK population-based registry. European Journal of Neurology 25(4), pp. 701-704. (10.1111/ene.13571)
• Tallantyre, E.et al. 2018. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. Journal of Neurology 265(5), pp. 1115-1122. (10.1007/s00415-018-8812-0)

2017

• Willis, M.et al. 2017. An observational study of alemtuzumab following fingolimod for multiple sclerosis. Neuroimmunology and Neuroinflammation 4(2), article number: E320. (10.1212/NXI.0000000000000320)

2016

• Tallantyre, E. C. and Robertson, N. P. 2016. Continuous evolution of magnetic resonance imaging in multiple sclerosis. Journal of Neurology 263(4), pp. 835-837. (10.1007/s00415-016-8099-y)
• Tallantyre, E. C., Wardle, M. and Robertson, N. 2016. How to run a multiple sclerosis relapse clinic. Practical Neurology 16(1), pp. 62-69. (10.1136/practneurol-2015-001214)

2015

• Thomas, R. H.et al. 2015. Why neurology? The career choices of current UK neurology trainees [Conference Abstract]. Journal of Neurology, Neurosurgery & Psychiatry 86(11), pp. e4., article number: 42. (10.1136/jnnp-2015-312379.42)
• Williams, O., Tallantyre, E. C. and Robertson, N. 2015. Traumatic brain injury: pathophysiology, clinical outcome and treatment. Journal of Neurology 262(5), pp. 1394-1396. (10.1007/s00415-015-7741-4)
• Tallantyre, E.et al. 2015. The aetiology of acute neurological decline in multiple sclerosis: Experience from an open-access clinic. Multiple Sclerosis Journal 21(1), pp. 67-75. (10.1177/1352458514538333)
• Tallantyre, E. C. and Robertson, N. 2015. Acute stroke management. Journal of Neurology 262(1), pp. 239-242. (10.1007/s00415-014-7607-1)

2013

• Tallantyre, E. C. and Robertson, N. 2013. Autism and intellectual disability. Journal of Neurology 260(3), pp. 936-939. (10.1007/s00415-013-6861-y)